Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis

NCT05485961 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT05485961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05485961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis
Lead sponsor
CSL Behring
Phase
Phase 2/3
Overall status
Recruiting
Start date
April 27, 2024
Completion date
May 22, 2029
Enrollment
3,110 (estimated)
Sites
566

Conditions

As the registry lists them; a condition with its own page is linked.

end stage kidney disease